<a href="https://www.fiercebiotech.com/medtech/medline-hit-fda-warning-letter-over-defective-heart-syringes-safety-hazards" hreflang="en">Medline hit with FDA warning letter over defective heart syringes, safety hazards</a>

For a professional tracking healthtech and biotech, the key learning here is the importance of robust regulatory compliance and ongoing engagement with the FDA, especially post-IPO. This situation underscores the critical need for companies to prioritize regulatory affairs to mitigate risks that can arise even after a successful public offering, impacting both reputation and market stability.